Copyright
©2014 Baishideng Publishing Group Inc.
World J Orthop. Sep 18, 2014; 5(4): 504-511
Published online Sep 18, 2014. doi: 10.5312/wjo.v5.i4.504
Published online Sep 18, 2014. doi: 10.5312/wjo.v5.i4.504
Table 2 Results summary for primary outcomes of phase 3 published trials
Primary outcomes | ORAL solo | ORAL step | ORAL standard | ORAL sync | ORAL scan | ||||||||||
Placebo(n = 122) | Tofacitinib 5 mg bid(n = 243) | Tofacitinib 10 mg bid(n = 245) | Placebo(n = 132) | Tofacitinib 5 mg bid(n = 133) | Tofacitinib 10 mg bid(n = 134) | Placebo(n = 108) | Tofacitinib 5 mg bid(n = 204) | Tofacitinib 10 mg bid(n = 201) | Placebo(n = 159) | Tofacitinib5 mgbid(n = 315) | Tofacitinib 10 mgbid(n = 318) | Placebo(n = 160) | Tofacitinib5 mgbid(n = 321) | Tofacitinib 10 mgbid(n = 316) | |
ACR20 response (%) | 26.7 | 59.8d | 65.7d | 24.4 | 41.7b | 48.1d | 28.3 | 51.5d | 52.6d | 30.8 | 52.1d | 56.6d | 25.3 | 51.5d | 61.8d |
Change from baselineHAQ-DI (LSM change) | -0.19 | -0.50d | -0.57d | -0.18 | -0.43d | -0.46d | -0.24 | -0.55a | -0.61a | -0.16 | -0.44d | -0.53d | -0.15 | 0.402 | -0.54d |
DAS-28-4(ESR) less than2.6 (%) | 4.4 | 5.61 | 8.71 | 1.7 | 6.7a | 8.8a | 1.1 | 6.2a | 12.5a | 2.6 | 8.5b | 12.5d | 1.6 | 7.22 | 16.0d |
- Citation: Lundquist LM, Cole SW, Sikes ML. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop 2014; 5(4): 504-511
- URL: https://www.wjgnet.com/2218-5836/full/v5/i4/504.htm
- DOI: https://dx.doi.org/10.5312/wjo.v5.i4.504